

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

Supplement material

Radical Cystectomy Practice Patterns in the Nordic Countries: Results from the Prospective NorCys Study

Venhomaa T et al.

Index

Supplemental Table 1A and B

Supplemental Table 2 A and B

Supplemental Table 3

Supplemental table 1.

Table S1A. Time from TUR-BT to radical cystectomy among NorCys study subjects undergoing radical cystectomy without neoadjuvant chemotherapy.

Characteristic (n, %)	Denmark N = 456	Finland N = 125	Iceland N = 9	Norway N = 74	Sweden N = 302	Overall N = 966 ¹
Time from TUR-BT to cystectomy (days) (914, 95%)						
< 30	96 (22%)	6 (5%)	0 (0%)	10 (14%)	17 (6%)	129 (14%)
30-50	219 (50%)	24 (21%)	1 (11%)	21 (30%)	51 (18%)	316 (35%)
50-70	72 (16%)	33 (29%)	3 (33%)	12 (17%)	80 (28%)	200 (22%)
70-90	14 (3%)	27 (24%)	1 (11%)	7 (10%)	60 (21%)	109 (12%)
90-110	11 (3%)	9 (8%)	1 (11%)	2 (3%)	37 (13%)	60 (6.6%)
> 110	25 (6%)	14 (12%)	3 (33%)	18 (26%)	40 (14%)	100 (11%)
Unknown	19	12	0	4	17	52

Table S1B. Time from TUR-BT to radical cystectomy among NorCys study subjects undergoing radical cystectomy after neoadjuvant chemotherapy.

Characteristic (n, %)	Denmark N = 227 ¹	Finland N = 103 ¹	Iceland N = 22 ¹	Norway N = 36 ¹	Sweden N = 170 ¹	Overall N = 558 ¹
Time from TUR-BT to cystectomy (days) (514, 92%)						
<100	29 (14%)	3 (4%)	1 (5%)	19 (53%)	21 (13%)	73 (14%)
100-120	44 (21%)	15 (19%)	11 (50%)	9 (25%)	36 (22%)	115 (22%)
120-140	69 (33%)	13 (16%)	5 (23%)	6 (17%)	31 (19%)	124 (24%)
140-160	23 (11%)	21 (26%)	2 (9%)	0 (0%)	17 (10%)	63 (12%)
160-180	17 (8%)	11 (14%)	1 (5%)	0 (0%)	23 (14%)	52 (10%)
>180	30 (14%)	18 (22%)	2 (9%)	2 (6%)	35 (21%)	87 (17%)
Unknown	15	22	0	0	7	44

Supplemental table 2.

Table S2A. Uni- and multivariate analysis of variables affecting use neoadjuvant chemotherapy in NorCys study.

Characteristic (n, %)	Univariate			Multivariate			
	No neoadjuvant N = 966 ¹	Yes neoadjuvant N = 558 ¹	Overall N = 1,524 ¹	p- value ²	OR	95% CI	p- value
Group (1524, 100%)				<0.001			
Denmark	456 (47%)	227 (41%)	683 (45%)		—	—	
Finland	125 (13%)	103 (18%)	228 (15%)		1.61	1.07, 2.42	0.022
Iceland	9 (1%)	22 (4%)	31 (2%)		5.96	2.32, 16.8	<0.001
Norway	74 (8%)	36 (6%)	110 (7%)		1.92	1.02, 3.60	0.043
Sweden	302 (31%)	170 (30%)	472 (31%)		1.03	0.75, 1.42	0.850
Age (1443, 95%)				<0.001	0.90	0.88, 0.92	<0.001
75 (70, 79)		69 (63, 73)	73 (66, 78)				
Gender (1524, 100%)				0.682			
Female	227 (23%)	126 (23%)	353 (23%)		—	—	
Male	739 (77%)	432 (77%)	1,171 (77%)		1.06	0.77, 1.46	0.718
BMI (1,475, 97%)				0.188	1.01	1.00, 1.02	0.038
26.3 (23.8, 29.4)		26.6 (24.0, 29.6)	26.4 (23.8, 29.4)				
ASA (1466, 95%)				0.823			
1	69 (7%)	41 (8%)	110 (8%)		—	—	
2	521 (56%)	308 (58%)	829 (57%)		1.24	0.72, 2.18	0.453
3	332 (36%)	176 (33%)	508 (35%)		1.50	0.84, 2.73	0.180
4	12 (1%)	7 (1%)	19 (1%)		1.38	0.40, 4.45	0.601
Smoking (466, 195%)				0.018			
Never	249 (28%)	126 (23%)	375 (26%)		—	—	
Former	507 (56%)	304 (56%)	811 (56%)		1.49	1.07, 2.08	0.019
Current	144 (16%)	116 (21%)	260 (18%)		1.23	0.81, 1.88	0.336
cT2 (1475, 97%)				<0.001			
≤T2	806 (87%)	429 (78%)	1,235 (84%)		—	—	
≥T3	116 (13%)	124 (22%)	240 (16%)		1.78	1.21, 2.61	0.003
cN (1438, 94%)				<0.001			
N0	857 (95%)	408 (76%)	1,265 (88%)		—	—	
N+	42 (5%)	131 (24%)	173 (12%)		8.57	5.45, 13.8	<0.001

Table S2B. Uni- and multivariate analysis of variables affecting use of robotic laparoscopic radical cystectomy vs. open radical cystectomy in NorCys study.

Characteristic	Univariate				Multivariate			
	N	Open N = 638 ¹	Robotic N = 902 ¹	Overall N = 1,540 ¹	p-value ²	OR	95% CI	p-value
Group (1540, 100%)	1,540				<0.001			
Denmark		95 (14%)	613 (68%)	708 (46%)		—	—	
Finland		209 (33%)	10 (1%)	219 (14%)		0.01	0.01, 0.02	<0.001
Iceland		2 (0%)	29 (3%)	31 (2%)		4.01	0.82, 72.3	0.178
Norway		61 (10%)	49 (5%)	110 (7%)		0.22	0.12, 0.40	<0.001
Sweden		271 (42%)	201 (22%)	472 (31%)		0.13	0.09, 0.18	<0.001
Age (1452, 94%)	1,452	74 (67, 78)	73 (66, 78)	73 (66, 78)	0.072	0.99	0.97, 1.01	0.238
Gender (1540, 100%)	1,540				0.853			
Female		149 (23%)	207 (23%)	356 (23%)		—	—	
Male		489 (77%)	695 (77%)	1,184 (77%)		1.16	0.83, 1.62	0.387
BMI (1490, 97%)	1,490	26.2 (23.6, 29.5)	26.6 (24.0, 29.4)	26.4 (23.9, 29.4)	0.191	1.01	1.00, 1.02	0.128
ASA (1494, 97%)	1,494				<0.001			
1		31 (5%)	83 (19%)	114 (8%)		—	—	
2		322 (52%)	519 (60%)	841 (56%)		0.92	0.51, 1.61	0.764
3		260 (42%)	260 (30%)	520 (35%)		0.65	0.35, 1.19	0.169
4		11 (2%)	8 (1%)	19 (1%)		0.50	0.12, 2.08	0.332
Smoking (1461, 95%)	1,461				0.029			
Never		177 (29%)	198 (23%)	375 (26%)		—	—	
Former		329 (54%)	495 (58%)	824 (56%)		0.83	0.59, 1.18	0.304
Current		100 (17%)	162 (19%)	262 (18%)		0.77	0.48, 1.22	0.261
cT-category (1490, 97%)	1,490				<0.001			
≤T2		468 (77%)	783 (88%)	1,251 (84%)		—	—	
≥T3		137 (23%)	102 (12%)	239 (16%)		0.78	0.52, 1.15	0.209
cN-category (1450, 94%)	1,450				0.090			
N0		508 (86%)	770 (89%)	1,278 (88%)		—	—	
N+		80 (14%)	92 (11%)	172 (12%)		1.10	0.71, 1.70	0.677

¹n (%); Median (Q1, Q3)

²Pearson's Chi-squared test; Wilcoxon rank sum test

Abbreviations: CI = Confidence Interval, OR = Odds Ratio

Table S3. Pathological staging in the Norcys study for patients with and without neoadjuvant chemotherapy prior to radical cystectomy.

Characteristic	N	No neoadjuvant chemotherapy N = 966	Neoadjuvant chemotherapy received N = 558	Overall N = 1,524
pT	1,314			
T0		187 (22%)	192 (40%)	379 (29%)
Ta–Tis–T1		273 (33%)	98 (21%)	371 (28%)
>T2		377 (45%)	187 (39%)	564 (43%)
Unknown		129	81	210
pN	1,438			
N0		649 (83%)	388 (84%)	1037 (72%)
N+		136 (17%)	76 (16%)	212 (15%)
Unknown		181	94	275